Silence Therapeutics Forms Scientific Advisory Board

23-Mar-2012 - Silence Therapeutics plc announced the creation of a Scientific Advisory Board (SAB) with the appointment of two Key Opinion Leaders (KOLs) in the area of liver disease, Professor Dr. Dr. Detlef Schuppan, M.D., PhD., and Professor Dr. Massimo Pinzani, M.D., PhD., F.R.C.P. The SAB will provide ...

Silence Therapeutics signs collaboration with miRagen Therapeutics to evaluate delivery of novel microRNA-based therapeutics

11-Jan-2012 - Silence Therapeutics plc announced that it has signed an agreement with miRagen Therapeutics, Inc. to assess the delivery potential of Silence’s proprietary DBTC delivery system with miRagen’s novel microRNA- (miRNA-) based therapeutics. Under the terms of the agreement, miRagen will provide ...

Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials

New Patent Broadens Company’s Existing Protection of Optimized RNAi Molecules Including Proprietary AtuRNAi Platform

25-Feb-2011 - Silence Therapeutics plc announced the issuance of United States patent 7,893,245, titled “Interfering RNA Molecules,” by the United States Patent and Trademark Office (USPTO). The issued patent, which represents a continuation of previously issued U.S. Patent Number 7,452,987, covers ...

Silence Therapeutics Receives Comprehensive Protection for RNAI Structural Modification Technology in Single European Patent

Wide-Ranging New Patent Broadly Covers Novel Aspects of “Zamore Design Rules”

26-Oct-2010 - Silence Therapeutics plc announced that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the “Zamore Design Rules.” European patent number 1 633 890 titled "Methods and Compositions ...

Silence Therapeutics Announces Issuance of Patent Covering Methods for Enhancing Silencing Activity of RNAi Therapeutics

Patent Covers Structural Modifications Associated with Innovative Zamore 'Design Rules'

14-Jun-2010 - Silence Therapeutics plc announced the issuance of United States patent 7,732,593, titled Methods and Compositions For Controlling Efficacy of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent, which is based on the seminal research of Phillip D. Zamore, ...

Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States

Company Supplements Broad RNAi IP Portfolio and Strengthens Growing Position in Oncology

01-Jun-2010 - Silence Therapeutics plc announced the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO). The issued patent, which deepens the ...

Silence Therapeutics Appoints New Vice President of Research

Move Bolsters Scientific Team at Company's Research Center in Berlin

11-May-2010 - Silence Therapeutics plc announced the promotion of Jorg Kaufmann, Ph.D., to the position of vice president of research. In this new position, Dr. Kaufmann, who previously served as senior director, technologies at Silence, will play a key role in overseeing the Company's range of RNA ...

Silence Therapeutics and AstraZeneca Extend siRNA Delivery Collaboration

27-Apr-2010 - Silence Therapeutics plc announced that the Company and AstraZeneca have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in March 2008, the companies are leveraging a number of ...

Silence Therapeutics Receives Notice of Allowance for RNA Interference Patent Covering Cancer Target

11-Feb-2010 - Silence Therapeutics plc announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology. Known as PKN-3, the target is a ...

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

01-Aug-2008 - Silence Therapeutics plc announced that its partner, Quark Pharmaceuticals Inc together with Pfizer, has commenced a Phase II clinical trial with RTP-801i-14 (PF-4523655), a small interfering RNA (siRNA) therapeutic product based on Silence's AtuRNAi technology. Its initiation triggers a $1.9 ...